{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:25:47Z","timestamp":1793453147648,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.ejpb.2011.03.016","type":"journal-article","created":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T01:33:09Z","timestamp":1301535189000},"page":"480-491","source":"Crossref","is-referenced-by-count":218,"title":["A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer\u00ae), a new intravenous iron preparation and its clinical implications"],"prefix":"10.1016","volume":"78","author":[{"given":"Markus R.","family":"Jahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans B.","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"F\u00fctterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Sch\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hofmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Meldal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2011.03.016_b0005","unstructured":"NICE-Guideline, Chronic Kidney Disease \u2013 National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care, National Institute for Health and Clinical Excellence, 2008."},{"key":"10.1016\/j.ejpb.2011.03.016_b0010","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfm014","article-title":"OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease","volume":"22","author":"Horl","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.ejpb.2011.03.016_b0015","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.3748\/wjg.15.4666","article-title":"Intravenous iron in inflammatory bowel disease","volume":"15","author":"Mu\u00f1oz","year":"2009","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0020","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ejpb.2011.03.016_b0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1423-0410.2007.01014.x","article-title":"Efficacy and safety of intravenous iron therapy as an alternative\/adjunct to allogeneic blood transfusion","volume":"94","author":"Mu\u00f1oz","year":"2008","journal-title":"Vox Sanguinis"},{"key":"10.1016\/j.ejpb.2011.03.016_b0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.6004\/jnccn.2008.0045","article-title":"Intravenous iron in oncology","volume":"6","author":"Auerbach","year":"2008","journal-title":"Journal of the National Comprehensive Cancer Network (JNCCN)"},{"key":"10.1016\/j.ejpb.2011.03.016_b0035","series-title":"Seminars in Hematology","first-page":"S39","article-title":"Intravenous iron in cardiac surgery","author":"Mu\u00f1oz","year":"2006"},{"key":"10.1016\/j.ejpb.2011.03.016_b0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2362.2000.00605.x","article-title":"Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis","volume":"30","author":"Breymann","year":"2000","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.ejpb.2011.03.016_b0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1755-6686.2009.00127.x","article-title":"Evolution of IV iron compounds over the last century","volume":"35","author":"Macdougall","year":"2009","journal-title":"Journal of Renal Care"},{"key":"10.1016\/j.ejpb.2011.03.016_b0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000046199","article-title":"Adverse events in chronic hemodialysis patients receiving intravenous iron dextran \u2013 a comparison of two products","volume":"20","author":"McCarthy","year":"2000","journal-title":"American Journal of Nephrology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0272-6386(01)80123-2","article-title":"Suspected iron dextran-related adverse drug events in hemodialysis patients","volume":"37","author":"Fletes","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1016\/j.ejpb.2011.03.016_b0060","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/ndt\/gfh185","article-title":"On the relative safety of parenteral iron formulations","volume":"19","author":"Chertow","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.ejpb.2011.03.016_b0065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/ndt\/gfi253","article-title":"Update on adverse drug events associated with parenteral iron","volume":"21","author":"Chertow","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.ejpb.2011.03.016_b0070","first-page":"1439","article-title":"Structure\/histotoxicity relationship of parenteral iron preparations","volume":"42","author":"Geisser","year":"1992","journal-title":"Arzneimittel-Forschung"},{"key":"10.1016\/j.ejpb.2011.03.016_b0075","unstructured":"Division of Medical Imaging and Hematology Products and Office of Oncology Drug Products and Office of New Drugs, New Drug Application 22-054 for Injectafer (Ferric Carboxymaltose) for the Treatment of iron Deficiency Anemia in Patients with Heavy Uterine Bleeding or Postpartum Patients, FDA Advisory Committee Briefing Document, 2008, pp. 1\u201363."},{"key":"10.1016\/j.ejpb.2011.03.016_b0080","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1159\/000230575","article-title":"Hapten inhibition of passive antidextran dextran anaphylaxis in guinea pigs. Role of molecular size in anaphylactogenicity and precipitability of dextran fractions","volume":"41","author":"Richter","year":"1971","journal-title":"International Archives of Allergy and Immunology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0085","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jvs.2005.11.056","article-title":"Invited commentary: pretreatment with dextran 1 makes dextran 40 therapy safer","volume":"43","author":"Ljungstr\u00f6m","year":"2006","journal-title":"Journal of Vascular Surgery"},{"key":"10.1016\/j.ejpb.2011.03.016_b0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/ajkd.2002.33917","article-title":"Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury","volume":"40","author":"Zager","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1016\/j.ejpb.2011.03.016_b0095","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1523-1755.2004.00716.x","article-title":"Parenteral iron nephrotoxicity: potential mechanisms and consequences","volume":"66","author":"Zager","year":"2004","journal-title":"Kidney International"},{"key":"10.1016\/j.ejpb.2011.03.016_b0100","series-title":"Polymer Characterization by Liquid Chromatography","author":"Gl\u00f6ckner","year":"1987"},{"key":"10.1016\/j.ejpb.2011.03.016_b0105","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.1990.tb07808.x","article-title":"Revised recommendations for the measurements of the serum iron in human blood. Iron panel of the international committee for standardization in haematology","volume":"75","author":"ICSH","year":"1990","journal-title":"British Journal Haematology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0110","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/clinchem\/17.9.950","article-title":"An autoanalyzer procedure for serum iron and total iron-binding capacity with use of ferrozine","volume":"19","author":"Yee","year":"1971","journal-title":"American Association of Clinical Chemistry"},{"key":"10.1016\/j.ejpb.2011.03.016_b0115","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0003-2697(71)90405-2","article-title":"Spectrophotometric determination of serum iron at the submicrogram level with a new reagent (ferrozine)","volume":"40","author":"Carter","year":"1971","journal-title":"Analytical Biochemistry"},{"key":"10.1016\/j.ejpb.2011.03.016_b0120","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1021\/ac50002a034","article-title":"Characterization and application of FerroZine iron reagent as a ferrous iron indicator","volume":"48","author":"Gibbs","year":"1976","journal-title":"Analytical Chemistry"},{"key":"10.1016\/j.ejpb.2011.03.016_b0125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2362.2009.02130.x","article-title":"Physicochemical properties of ferumoxytol, a new intravenous iron preparation","volume":"39","author":"Balakrishnan","year":"2009","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.ejpb.2011.03.016_b0130","unstructured":"H.B. Andreasen, L. Christensen, Iron-dextran compound for the use as component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, US Patent 6291,440, 2001."},{"key":"10.1016\/j.ejpb.2011.03.016_b0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1018944113914","article-title":"Evaluation of the physical stability of freeze-dried sucrose-containing formulations by differential scanning calorimetry","volume":"9","author":"te Booy","year":"1992","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.ejpb.2011.03.016_b0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/07328309408011662","article-title":"A conformational study of hydroxymethyl groups in carbohydrates investigated by 1H NMR spectroscopy","volume":"13","author":"Bock","year":"1994","journal-title":"Journal Carbohydrate Chemistry"},{"key":"10.1016\/j.ejpb.2011.03.016_b0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jmmm.2005.01.045","article-title":"Magnetostructural study of iron sucrose","volume":"293","author":"Guti\u00e9rrez","year":"2005","journal-title":"Journal of Magnetism and Magnetic Materials"},{"key":"10.1016\/j.ejpb.2011.03.016_b0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1015552311359","article-title":"Physical and chemical characterization of therapeutic iron containing materials: a study of several superparamagnetic drug formulations with the \u03b2-FeOOH or ferrihydrite structure","volume":"136","author":"Funk","year":"2001","journal-title":"Hyperfine Interactions"},{"key":"10.1016\/j.ejpb.2011.03.016_b0155","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jinorgbio.2004.06.010","article-title":"Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations","volume":"98","author":"Kudasheva","year":"2004","journal-title":"Journal of Inorganic Biochemistry"},{"key":"10.1016\/j.ejpb.2011.03.016_b0160","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/elps.200600559","article-title":"CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA","volume":"28","author":"Jahn","year":"2007","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ejpb.2011.03.016_b0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4049\/jimmunol.86.3.241","article-title":"Some observations on the immunochemistry of dextrans","volume":"86","author":"Coulson","year":"1961","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000230841","article-title":"Minimal molecular size of dextran required to elicit heterologous passive cutaneous anaphylaxis in guinea pigs","volume":"43","author":"Richter","year":"1972","journal-title":"International Archives of Allergy and Immunology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0175","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1159\/000231091","article-title":"Built-in hapten inhibition of anaphylaxis by the low molecular weight subfractions of a B 512 dextran fraction of Mw 3400","volume":"45","author":"Richter","year":"1973","journal-title":"International Archives of Allergy and Applied Immunology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0180","series-title":"Immune Complex Anaphylaxis Induced by Dextran and Its Elimination by Hapten Inhibition","author":"Richter","year":"1986"},{"key":"10.1016\/j.ejpb.2011.03.016_b0185","first-page":"179","article-title":"Incidence, pathomechanism and prevention of dextran-induced anaphylactoid\/anaphylactic reactions in man","volume":"48","author":"Hedin","year":"1980","journal-title":"Developments in Biological Standardization"},{"key":"10.1016\/j.ejpb.2011.03.016_b0190","first-page":"355","article-title":"Prevention of dextran induced anaphylactic reaction by hapten inhibition","volume":"149","author":"Renck","year":"1983","journal-title":"Acta Chirurgica Scandinavica"},{"key":"10.1016\/j.ejpb.2011.03.016_b0195","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000222845","article-title":"Safety of dextran in relation to other colloids \u2013 ten years experience with hapten inhibition","volume":"20","author":"Ljungstr\u00f6m","year":"1993","journal-title":"Transfusion Medicine and Hemotherapy"},{"issue":"Suppl. 2","key":"10.1016\/j.ejpb.2011.03.016_b0200","first-page":"S99","article-title":"Safety of intravenous iron in clinical practice: implications for anemia management protocols","volume":"15","author":"Aronoff","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.20056","article-title":"Parenteral iron therapy options","volume":"76","author":"Silverstein","year":"2004","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1525-139x.2000.00104.x","article-title":"The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate","volume":"13","author":"Fishbane","year":"2000","journal-title":"Seminars in Dialysis"},{"issue":"Suppl. 2","key":"10.1016\/j.ejpb.2011.03.016_b0215","first-page":"S93","article-title":"Structure, chemistry, and pharmacokinetics of intravenous iron agents","volume":"15","author":"Danielson","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajh.21656","article-title":"FDA review of ferumoxytol (Feraheme) for the treatment of iron deficiency anemia in adults with chronic kidney disease","volume":"85","author":"Lu","year":"2010","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ajh.21682","article-title":"Anemia management in chronic kidney disease: intravenous iron steps forward","volume":"85","author":"Coyne","year":"2010","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.ejpb.2011.03.016_b0230","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tmrv.2006.05.002","article-title":"Serious hazards of transfusion: a decade of hemovigilance in the UK","volume":"20","author":"Stainsby","year":"2006","journal-title":"Transfusion Medicine Reviews"},{"key":"10.1016\/j.ejpb.2011.03.016_b0235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/ndtplus\/sfq084","article-title":"Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol","volume":"3","author":"Santosh","year":"2010","journal-title":"NDT Plus"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111001172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111001172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T11:55:51Z","timestamp":1712318151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641111001172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0939641111001172"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2011.03.016","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}